BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 33085221)

  • 21. Impact of Pharmacogenomics on Pediatric Psychotropic Medication Prescribing in an Ambulatory Care Setting.
    Tonti E; Lee YM; Gruenke N; Ferren J; Stutzman DL
    J Child Adolesc Psychopharmacol; 2024 Feb; 34(1):52-60. PubMed ID: 38377527
    [No Abstract]   [Full Text] [Related]  

  • 22. Evaluation of population-level pharmacogenetic actionability in Alabama.
    Davis BH; Williams K; Absher D; Korf B; Limdi NA
    Clin Transl Sci; 2021 Nov; 14(6):2327-2338. PubMed ID: 34121327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenomic profile of a central European urban random population-Czech population.
    Proietti R; Maranho Neto GA; Kunzova S; Lo Re O; Ahola-Olli A; Heliste J; Gonzalez-Rivas JP; Vinciguerra M
    PLoS One; 2023; 18(4):e0284386. PubMed ID: 37079615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Pharmacogenomic Phenotypes in CYP2D6, CYP2C9, CYP2C19, and CYP3A5 on Polypharmacy in Veterans.
    Krulikas L; Bates J; Chanfreau C; Coleman H; Dalton S; Voora D
    Clin Pharmacol Ther; 2024 May; ():. PubMed ID: 38775021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population.
    Verma SS; Keat K; Li B; Hoffecker G; Risman M; ; Sangkuhl K; Whirl-Carrillo M; Dudek S; Verma A; Klein TE; Ritchie MD; Tuteja S
    J Transl Med; 2022 Nov; 20(1):550. PubMed ID: 36443877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population.
    Dorji PW; Wangchuk S; Boonprasert K; Tarasuk M; Na-Bangchang K
    Drug Metab Pers Ther; 2019 Dec; 34(4):. PubMed ID: 32004143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opportunities for Pharmacogenetic Testing to Guide Dosing of Medications in Youths With Medicaid.
    Tang Girdwood S; Hall M; Antoon JW; Kyler KE; Williams DJ; Shah SS; Orth LE; Goldman J; Feinstein JA; Ramsey LB
    JAMA Netw Open; 2024 Feb; 7(2):e2355707. PubMed ID: 38349656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prescription Patterns and Relationship to Pharmacogenomics Testing in the Military Health System.
    Selig DJ; Livezey JR; Chin GC; DeLuca JP; Guillory Ii WO; Kress AT; Oliver TO; Por ED
    Mil Med; 2021 Dec; 187(Suppl 1):9-17. PubMed ID: 34967405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review of pharmacogenetic studies in the Bangladeshi population.
    Mostaid MS; Aziz MA; Maisha JA; Islam MS; Maruf AA
    Drug Metab Pers Ther; 2023 Jun; 38(2):123-131. PubMed ID: 36854045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potentially actionable pharmacogenetic variants and symptom control medications in oncology.
    Patel JN; Boselli D; Jandrisevits EJ; Hamadeh IS; Salem A; Meadors P; Walsh D
    Support Care Cancer; 2021 Oct; 29(10):5927-5934. PubMed ID: 33758969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing.
    Reizine NM; Danahey K; Truong TM; George D; House LK; Karrison TG; van Wijk XMR; Yeo KJ; Ratain MJ; O'Donnell PH
    Cancer; 2022 Apr; 128(8):1649-1657. PubMed ID: 35090043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of drugs with pharmacogenomics (PGx)-based dosing guidelines in a Danish cohort of persons with chronic kidney disease, both on dialysis and not on dialysis: Perspectives for prescribing optimization.
    Westergaard N; Baltzer Houlind M; Christrup LL; Juul-Larsen HG; Strandhave C; Olesen AE
    Basic Clin Pharmacol Toxicol; 2024 Apr; 134(4):531-542. PubMed ID: 38308569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Computational pharmacogenotype extraction from clinical next-generation sequencing.
    Shugg T; Ly RC; Osei W; Rowe EJ; Granfield CA; Lynnes TC; Medeiros EB; Hodge JC; Breman AM; Schneider BP; Sahinalp SC; Numanagić I; Salisbury BA; Bray SM; Ratcliff R; Skaar TC
    Front Oncol; 2023; 13():1199741. PubMed ID: 37469403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Relevance of a 16-Gene Pharmacogenetic Panel Test for Medication Management in a Cohort of 135 Patients.
    Niedrig DF; Rahmany A; Heib K; Hatz KD; Ludin K; Burden AM; Béchir M; Serra A; Russmann S
    J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34361984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients.
    Jessel CD; Mostafa S; Potiriadis M; Everall IP; Gunn JM; Bousman CA
    Pharmacogenet Genomics; 2020 Sep; 30(7):145-152. PubMed ID: 32433340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy.
    Tuteja S; Salloum RG; Elchynski AL; Smith DM; Rowe E; Blake KV; Limdi NA; Aquilante CL; Bates J; Beitelshees AL; Cipriani A; Duong BQ; Empey PE; Formea CM; Hicks JK; Mroz P; Oslin D; Pasternak AL; Petry N; Ramsey LB; Schlichte A; Swain SM; Ward KM; Wiisanen K; Skaar TC; Van Driest SL; Cavallari LH; Bishop JR;
    Clin Transl Sci; 2022 Feb; 15(2):371-383. PubMed ID: 34562070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Attitudes toward pharmacogenetics in patients undergoing
    Lee G; Varughese LA; Conway L; Stojinski C; Ashokkumar S; Monono K; Matthai W; Kolansky DM; Giri J; Tuteja S
    Per Med; 2022 Mar; 19(2):93-101. PubMed ID: 34984913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice.
    Russmann S; Rahmany A; Niedrig D; Hatz KD; Ludin K; Burden AM; Englberger L; Backhaus R; Serra A; Béchir M
    Eur J Clin Pharmacol; 2021 May; 77(5):709-716. PubMed ID: 33242107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted Genotyping in Clinical Pharmacogenomics: What Is Missing?
    Lopes JL; Harris K; Karow MB; Peterson SE; Kluge ML; Kotzer KE; Lopes GS; Larson NB; Bielinski SJ; Scherer SE; Wang L; Weinshilboum RM; Black JL; Moyer AM
    J Mol Diagn; 2022 Mar; 24(3):253-261. PubMed ID: 35041929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases.
    Zhu Y; Swanson KM; Rojas RL; Wang Z; St Sauver JL; Visscher SL; Prokop LJ; Bielinski SJ; Wang L; Weinshilboum R; Borah BJ
    Genet Med; 2020 Mar; 22(3):475-486. PubMed ID: 31591509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.